On August 24, WUXI APPTEC declined 3.06% in regular trading to HKD 199.7/share, with turnover of HKD 189 million. The broader Life Sciences Tools & Services sector saw widespread selling, with peers WUXI BIO down 4.27%, WUXI XDC down 4.12%, and GENSCRIPT BIO down 3.6%.

The pullback follows a sharp rally that drove the H-share above HKD 200 to record highs earlier this month. The prior week saw institutional net selling of RMB 10.34 million on the A-share, while main fund net outflows reached RMB 351 million on August 21, signaling profit-taking after multiple positive catalysts had been priced in — including a US court preliminary injunction against the 1260H designation, strong first-half earnings (revenue up 38.93% YoY, net profit exceeding RMB 11 billion), and target price upgrades from Bank of America (HKD 242) and Daiwa (HKD 230). With gains accumulated rapidly, the sector appears to be digesting recent advances.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)